Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 46Cisplatin 31Carboplatin 20Cetuximab 16Nivolumab 15Paclitaxel 14Radiotherapy, Intensity-Modulated 12Radiotherapy 10Docetaxel 10Fluorouracil 9Platinum 8durvalumab 7Taxes 71,2-diaminocyclohexaneplatinum II citrate 7Radiation 6tislelizumab 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5cemiplimab 4avelumab 4Specimen Handling 4Radiosurgery 4Drug Therapy 4Biopsy 4130-nm albumin-bound paclitaxel 4tremelimumab 3palbociclib 3olaparib 3dostarlimab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Squamous Cell Carcinoma of Head and Neck × berzosertib × Clear all
NCT02567422 2026-06-02

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
43 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡